Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimis
A drug developed by US biotech Akero Therapeutics has hit the mark in a phase 2b trial in non-alcoholic steatohepatitis (NASH) – catapulting it to the forefront of efforts to find effective